Clinicopathological and molecular characterization of SMARCA4-deficient thoracic sarcomas with comparison to potentially related entities
Modern Pathology2017Vol. 30(6), pp. 797–809
Citations Over TimeTop 10% of 2017 papers
Akihiko Yoshida, Eisuke Kobayashi, Takashi Kubo, Makoto Kodaira, Toru Motoi, Noriko Motoi, Kan Yonemori, Yuichiro Ohe, Shun‐ichi Watanabe, Akira Kawai, Takashi Kohno, Hiroshi Kishimoto, Hitoshi Ichikawa, Nobuyoshi Hiraoka
Related Papers
- → The SWI/SNF chromatin-remodeling complex status in renal cell carcinomas with sarcomatoid or rhabdoid features(2020)13 cited
- → Assessing the significance of KRAS G12C mutation: Clinicopathologic features, treatments, and survival outcomes in a real-world KRAS mutant non-small cell lung cancer cohort.(2020)3 cited
- → P35.02 Lung Adenocarcinoma with Oncogenic SMARCA4 Mutation: Possible Target of Cancer Immunotherapy(2021)
- → 127P RAS, RAF and NF1 oncogenic mutations in KRAS-mutated lung adenocarcinoma(2022)
- → EP06.05-01 Molecular, Clinicopathological Characteristics of Thoracic SMARCA4-defcientUndifferentiated Malignant Tumor -5 Cases Review(2023)